PASG
Passage Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$29.80M
P/E Ratio
—
EPS
$-14.35
Beta
1.76
52W High
$20.00
52W Low
$5.12
50-Day MA
$8.83
200-Day MA
$8.56
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Passage Bio Inc
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-42.42M |
| Operating Margin | 0.00% |
| Return on Equity | -113.80% |
| Return on Assets | -32.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.89 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.21M |
| Float | $2.89M |
| % Insiders | 0.20% |
| % Institutions | 51.67% |
Analyst Ratings
Consensus ($30.67 target)
6
BuyData last updated: 4/9/2026